MIDOL COMPLETE OTC
Generic Name and Formulations:
Acetaminophen 500mg, caffeine 60mg, pyrilamine maleate 15mg; caplets.
Bayer Corp, Consumer Care Div.
Indications for MIDOL COMPLETE:
2 caplets every 6hrs; max 6/day.
<12yrs: consult physician.
Concomitant other acetaminophen-containing products.
Acetaminophen: hepatic disease. Pyrilamine: asthma, emphysema, other lower respiratory disorders. Glaucoma. GI or urinary obstruction. Discontinue if skin or allergic reactions occur. Reevaluate if pain worsens or lasts >10 days or fever persists or worsens >3 days. Pregnancy. Nursing mothers.
Acetaminophen: increased risk of hepatotoxicity if overdosage or ≥3 alcoholic drinks/day. Pyrilamine: potentiates CNS depression with alcohol, other CNS depressants. Caution with warfarin, sedatives, or tranquilizers.
Analgesic + diuretic + sedating antihistamine.
Acetaminophen: hepatotoxicity (overdosage). Pyrilamine: drowsiness, dizziness, paradoxical excitation (esp. in children). Caffeine: nervousness, irritability, sleeplessness, occasional palpitations.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|